What's Happening?
Eli Lilly & Company (LLY) and Pfizer Inc. (PFE), two major U.S. pharmaceutical companies, are navigating distinct growth paths. Eli Lilly has established a strong presence in the cardiometabolic market, driven by the high demand for its GLP-1 drugs, Mounjaro
and Zepbound, which generated $43.8 billion in combined sales in the first nine months of 2026. The company is also expanding its portfolio with new therapies like Foundayo, an oral GLP-1 pill for obesity, and is developing next-generation GLP-1 treatments, including Retatrutide. Pfizer, conversely, is diversifying its portfolio beyond its previous heavy reliance on COVID-19 products. Its oncology business remains a key growth area, with oncology sales growing 6% in the first nine months of 2026. Pfizer is also investing in new product launches and strategic acquisitions, such as Seagen and Metsera, to mitigate upcoming patent expirations and rebuild its pipeline in oncology and obesity.
Why It's Important?
The competition between Eli Lilly and Pfizer highlights significant trends in the U.S. pharmaceutical industry. Eli Lilly's success with GLP-1 drugs underscores the immense market potential for obesity and diabetes treatments, potentially reshaping healthcare approaches for these widespread conditions. The introduction of oral GLP-1 options like Foundayo could significantly improve patient convenience and market penetration. For Pfizer, the strategic shift away from COVID-19 product dependency and its focus on oncology and new acquisitions are crucial for long-term sustainability, especially as it faces a substantial patent cliff later this decade. The performance of these companies directly impacts investors, healthcare providers, and patients, influencing drug accessibility, pricing, and the direction of pharmaceutical research and development in critical therapeutic areas.
What's Next?
Eli Lilly plans to seek FDA approval for Retatrutide, a multi-acting GLP-1 candidate, in the first quarter of 2027, which could become another multi-billion-dollar growth driver. The company also anticipates continued growth from its existing GLP-1 drugs due to increasing patient demand and broader insurance coverage. Pfizer aims to advance over 20 studies for obesity and related comorbidities in 2026, with potential approvals for its investigational GLP-1 receptor agonist, berobenatide, targeted for 2028. Pfizer also expects to initiate additional Phase III studies for its oncology candidate, tivunatamig, before year-end. Both companies will continue to face challenges, including pricing pressures for Lilly and the impact of patent expirations for Pfizer, which expects a negative revenue impact of approximately $1.1 billion in 2026 from loss of exclusivity.
Beyond the Headlines
The divergent strategies of Eli Lilly and Pfizer reflect broader industry dynamics, including the increasing specialization in high-demand therapeutic areas like cardiometabolic diseases and oncology, and the ongoing challenge of managing patent expirations. Eli Lilly's aggressive acquisition strategy to diversify its pipeline beyond GLP-1 drugs indicates a proactive approach to long-term growth and risk mitigation. Pfizer's efforts to rebuild its pipeline and reduce costs highlight the necessity for pharmaceutical giants to continuously innovate and adapt to market shifts. The success of oral GLP-1 medications could also signal a significant shift in drug delivery preferences, potentially influencing future pharmaceutical development across various conditions. These developments have implications for healthcare policy, insurance coverage, and the competitive landscape of the global pharmaceutical market.













